Show simple item record

dc.contributor.authorvan der Heiden, Marieke
dc.contributor.authorBoots, Annemieke M H
dc.contributor.authorBonacic Marinovic, Axel A
dc.contributor.authorde Rond, Lia G H
dc.contributor.authorvan Maurik, Marjan
dc.contributor.authorTcherniaeva, Irina
dc.contributor.authorBerbers, Guy A M
dc.contributor.authorBuisman, Anne-Marie
dc.date.accessioned2018-01-09T12:14:58Z
dc.date.available2018-01-09T12:14:58Z
dc.date.issued2017
dc.identifier.citationNovel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults. 2017, 8:817 Front Immunolen
dc.identifier.issn1664-3224
dc.identifier.pmid28769927
dc.identifier.doi10.3389/fimmu.2017.00817
dc.identifier.urihttp://hdl.handle.net/10029/621055
dc.description.abstractVaccine responses are often reduced in the elderly, leaving part of the elderly population vulnerable to infectious diseases. Timely vaccination may offer a solution for strengthening memory immunity before reaching old age, which classifies middle-aged persons as a target age group for vaccine interventions. However, knowledge regarding the immunogenicity of primary immunizations in middle-aged adults is lacking. We determined the immunogenicity of a primary meningococcal vaccine towards which no or (very) low pre-vaccination immunity exists in middle-aged adults (NTR4636).
dc.language.isoenen
dc.rightsArchived with thanks to Frontiers in immunologyen
dc.titleNovel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults.en
dc.typeArticleen
dc.identifier.journalFront Immunol 2017, 8:817en
html.description.abstractVaccine responses are often reduced in the elderly, leaving part of the elderly population vulnerable to infectious diseases. Timely vaccination may offer a solution for strengthening memory immunity before reaching old age, which classifies middle-aged persons as a target age group for vaccine interventions. However, knowledge regarding the immunogenicity of primary immunizations in middle-aged adults is lacking. We determined the immunogenicity of a primary meningococcal vaccine towards which no or (very) low pre-vaccination immunity exists in middle-aged adults (NTR4636).


This item appears in the following Collection(s)

Show simple item record